LBRX compared with IPSC: revenue, margins and what each company keeps, and the suppliers and customers both name

LBRXLB Pharmaceuticals Inc

Mkt capRevenueRevenue

IPSCCentury Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LBRXLB Pharmaceuticals Inc

IPSCCentury Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LBRX

Reportimpliedrealized× implied

Q2 FY26—▼−1.13%—

May 13 '26—▲+3.79%—

Q1 FY26—▼−2.81%—

Q3 FY25—▼−4.26%—

IPSC1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±29.8%▼−4.85%×0.16

= impliedLBRX realized, solidIPSC realized, hatchedOne scale, both sides: full bar = 30%× = |realized| ÷ impliedSource: market data

LBRXLB Pharmaceuticals Inc

39.10· pre 39.09· delayed

Mkt cap$1.2BRevenue—Revenue—

IPSCCentury Therapeutics, Inc.

1.47· pre 1.47· delayed

Pre-marketNov 2 '26delayed

Mkt cap$266.2MRevenue$109MQ1 FY25Revenue$7MFY24

Compare

Pre-marketNov 2 '26delayed

LBRXLB Pharmaceuticals Inc

IPSCCentury Therapeutics, Inc.

39.10pre 39.09delayed

Price

1.47pre 1.47delayed

$1.2B

Mkt cap

$266.2M

—

Revenue

$109MQ1 FY25

—

Revenue

$7MFY24

LBRX39.10vsIPSC1.47Pre-marketNov 2 '26delayed